Dear Albert,
The new data included in the Platform is a complete rewrite of all pipelines and analysis, so we effectively started from scratch to produce the data and view that we believe should enhance our ability to find new drug targets.
As part of the re-design, every feature and user journey was scrutinised to understand the cost-benefit of each feature and decide on the minimal viable product that would give us a sustainable impact on target selection.
Unfortunately, the scale and complexity of the change imply that data and services are not backwards compatible. However, most of the use cases should still remain either through similar or different views on the same data.
We are happy to help you and others through this transition. If you have any particular use case, or anything that you would like to do but you don’t know how, please open a new post and hopefully others will benefit from your question.
I hope this helps 